This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Stories That Hit Headlines in 2020
by Sweta Killa
With super-easy policies and vaccination, small-cap stocks like Liquidity Services (LQDT) and cyclical stocks like Nexstar Media (NXST), Deere & Company (DE) and BHP Billiton (BBL) are expected to benefit the most.
Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal
by Zacks Equity Research
Aprea (APRE) down as late-stage study on lead candidate, eprenetapopt, combined with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS) fails.
Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.
Amgen/AstraZeneca's Asthma Drug Misses Phase III Study Goal
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) plan to file regulatory applications for tezepelumab next year.
Stock Market News for Dec 23, 2020
by Zacks Equity Research
Benchmarks closed mixed on Tuesday as investors remained concerned about rising coronavirus cases in America and Europe despite a vaccine rollout in progress and additional stimulus package.
Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe
by Zacks Equity Research
The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
Merck (MRK) Gets FDA's Priority Review for Another Keytruda sBLA
by Zacks Equity Research
The FDA accepts Merck's (MRK) sBLA for Keytruda combo for first-line metastatic esophageal and gastroesophageal junction cancer, under a priority review. The FDA's verdict is awaited on Apr 13, 2021.
Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer
by Zacks Equity Research
The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for Two New Indications
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rinvoq for treating active psoriatic arthritis and active ankylosing spondylitis.
Merck (MRK) Keytruda Gets CHMP Nod for First-Line Colon Cancer
by Zacks Equity Research
Merck's (MRK) regulatory application seeking label expansion of Keytruda as first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer gets positive CHMP opinion.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $227.40 in the latest trading session, marking a -0.33% move from the prior day.
AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study
by Zacks Equity Research
AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.
Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News
by Zacks Equity Research
Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.
Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.
Top Stock Reports for Facebook, Netflix & AbbVie
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Netflix, Inc. (NFLX) and AbbVie Inc. (ABBV).
FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication
by Zacks Equity Research
FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.
Amgen (AMGN) Up 1.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More
by Zacks Equity Research
Pipeline and regulatory updates take centerstage in the biotech sector as Regeneron (REGN) and Gilead Sciences (GILD), among others, provide updates on their pipeline candidates.
Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate
by Zacks Equity Research
Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.
Sanofi (SNY) Pompe Disease Drug Gets FDA's Priority Tag
by Zacks Equity Research
The FDA gives priority review tag to Sanofi's (SNY) avalglucosidase alfa for Pompe disease and Fast Track status to rilzabrutinib for immune thrombocytopenia.
Merck's (MRK) Keytruda Gets FDA Nod for Severe Breast Cancer
by Zacks Equity Research
The FDA approves Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer. This marks the first nod for Keytruda in the breast cancer setting.
Should Value Investors Pick Amgen (AMGN) Stock Right Now?
by Zacks Equity Research
Is Amgen (AMGN) a great pick from the value investor's perspective right now? Read on to know more.
AstraZeneca's (AZN) Asthma Drug Meets Primary Goal in Phase III
by Zacks Equity Research
AstraZeneca's (AZN) pipeline candidate tezepelumab achieves the primary goal in phase III NAVIGATOR study for addressing patients with severe, uncontrolled asthma.
Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Radius' (RDUS) Q3 Loss Matches Estimates, Revenues Miss
by Zacks Equity Research
Radius (RDUS) reports an in-line loss but misses sales estimates in the third quarter.